FormalPara Key summary points

Oral enzyme combination (OEC) therapy is being studied to treat a variety of conditions, including inflammation, oncology, and trauma.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most prescribed pharmaceutical treatment for the most common joint disorder worldwide – osteoarthritis (OA).

The long-term use of NSAIDs in osteoarthritis is associated with several potentially serious side effects.

Study outcomes following use of an OEC therapy combination containing the proteolytic enzymes bromelain and trypsin in addition to the plant flavonoid rutin in patients with OA suggest that this OEC is as effective as NSAIDs but with a superior side effect profile.

Digital Features

This article is published with digital features, including an infographic, to facilitate understanding of the article. To view digital features for this article, go to


Inflammation is the body’s natural immune response to a variety of harmful stimuli, including tissue injury and progressive diseases. Even if chronic and acute forms of inflammation are clinically burdensome for patients owing to the pain, swelling, and functional limitations, inflammation is also an important step that contributes to the healing process. Without the inflammation step, the healing process may be incomplete [1]. During inflammation, cytokines are released in the affected area, with pro-inflammatory and anti-inflammatory cytokines playing a central role in balancing the inflammatory responses [2]. Acute inflammatory conditions can result from sports injuries or following surgery [3,4,5,6]. In some instances, inflammation may become unregulated and develop into a chronic condition such as osteoarthritis (OA).

Inflammatory conditions such as OA are commonly managed using nonsteroidal anti-inflammatory drugs (NSAIDs) [7,8,9]. However, long-term use of NSAIDs is associated with several adverse events [10] and a link between NSAID use and progression of radiographic knee OA has recently been suggested [11], limiting treatment options even further. NSAIDs may further disrupt the resolution (e.g., active healing) process of inflammation by, for example, blockade of cyclooxygenase (COX-2), which prevents the release of specialized pro-resolving mediators [12]. Complementary therapy including systemic enzyme therapy or oral enzyme combination (OEC) is a potential new approach in managing inflammatory conditions. The scientific evidence underlining the efficacy of OECs in the treatment of patients with OA includes nine small-scale clinical trials (with up to 268 subjects) and a systematic literature review with a pooled individual patient-level meta-analysis of data from six randomized controlled trials (RCT), comparing OEC to the NSAID diclofenac in patients with OA of the knee [13].

In this narrative review, we will summarize the evidence of the efficacy of existing enzyme therapy treatments and specifically focus on efficacy in OA. This paper includes a search in PubMed using the following terms ‘osteoarthritis’, ‘systemic enzyme therapy’, ‘oral enzyme combination’, and ‘proteolytic enzymes’ with relevant literature selected for review. Animal or in vitro studies were included to enhance the understanding of the mode of action of oral proteolytic enzyme combinations and the flavonoid rutin (or rutoside). This paper is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Enzyme Therapy History

The administration of plant extracts with high proteolytic enzyme content (systemic enzyme therapy) originates from the use of traditional medicine in Central and South America [14]. It is currently being studied to treat a variety of conditions, including those associated to oncology, trauma, and inflammation [13,14,15,16]. In 1902, John Beard published a scientific article in The Lancet proposing enzymatic treatment of patients with cancer. He then published the scientific rationale of systemic enzyme therapy in 1911, ‘The Enzyme Treatment of Cancer and its Scientific Basis’ [17]. However, his work had been largely forgotten until the 1950s when Max Wolf and Helene Benitez developed the concept of systemic enzyme therapy for oncology [14]. They observed that systemic enzyme therapy, including a combination of plant and animal proteinases, exerted anti-cancer effects by restoring the reduced cytotoxic activity of patients’ sera [18].

The systematic enzyme therapy combination most frequently used in oncology has consisted of a combination of papain, trypsin, and chymotrypsin [14]. A review of a number of RCTs in Germany using systematic enzyme therapy as an adjunctive treatment with radiotherapy and chemotherapy highlighted how systematic enzyme therapy can reduce the severity adverse effects caused by radiotherapy and chemotherapy [14].

OEC therapy was also investigated in low-grade inflammation and in the treatment of delayed-onset muscle soreness [19, 20]. An open trial conducted by Kameníček et al. [16] demonstrated the superiority of an OEC containing bromelain and trypsin combined with rutin as active ingredients, over escin-based anti-edematous drugs, in the prophylaxis of post-surgical edema following osteosynthesis of the long bones of the extremities. A randomized, placebo-controlled clinical trial investigating the same OEC reported significant favorable effects on fatigue, muscle soreness, and damage, as well as on immunological and metabolic biomarkers in healthy active adults after exhaustive eccentric exercise [19].


OA is a chronic inflammatory disease that is often referred to as a degenerative joint disease. In addition to wear and tear, OA is also characterized by abnormal remodeling of the joint, bone, cartilage, ligaments, fat, and the synovium, caused by a number of inflammatory mediators within the affected joint [21]. The main hallmarks of OA recognized by the patient include a loss of normal joint movement, stiffness, swelling, and pain [22]. Clinical OA is defined by features in the patient’s clinical history and on medical examination, with the classification of idiopathic OA of the knee including joint pain in addition to at least three of the following criteria: age over 50 years, stiffness for more than 30 min, crepitus, bony tenderness, bony enlargement, or no palpable warmth [23, 24]. Subjective OA relies on the assessment of the patient as to whether the disease is present, with a poor correlation to radiographic structural changes [23].

The prevalence of OA is rising owing to the increase in risk factors, particularly ageing, and a rise in obesity due to a sedentary lifestyle [25]. The global number of people aged 65 years or older is projected to more than double, reaching over 1.5 billion persons by 2050 [26], consequently leading to an expected increase in OA cases. Knee OA accounts for 83% of the total OA burden and is the most common OA localization in persons aged 40 years and over; symptomatic knee OA is highly prevalent among people aged over 50 years, affecting more than 250 million people worldwide [27, 28].

Chronic inflammation is linked to the onset and development of OA and can be caused by long-term tissue exposure to stressors [29, 30]. There are two types of stressors involved in joint tissue damage that links obesity and OA—the direct effect of mechanical load, and the effect of adipocytes inducing micro-inflammatory processes when the adipose tissue is ectopic [31]. Some of the hallmarks of ageing such as age-related inflammation (also known as inflammaging) and cellular senescence (including the senescence-associated secretory phenotype [SASP]) could also contribute to the development of OA [32,33,34]. The production of pro-inflammatory cytokines is one of the key features of SASP [34,35,36]. The potency of senescent cells in shortening health- and lifespan was indicated in an animal study in which transplantation of senescent cells into older mice resulted in persistent physical dysfunction, as well as spreading cellular senescence to host tissue and reducing survival [37].

As OA is a progressive disease that spans decades of a patient’s life, with varying degrees of severity, the long-term management of OA usually includes several pharmaceutical and non-pharmaceutical interventions. Currently available treatments aim to reduce symptoms of inflammation (particularly pain), maintain joint mobility, and limit the loss of function [22, 38]. The reduction of pain and inflammation in patients with OA can increase compliance and participation in exercise programs, further contributing to improved quality of life [39].

Symptoms of OA are commonly managed using NSAIDs [7,8,9]. Existing treatment guidelines from prominent professional societies for patients with OA recommend oral NSAIDs but limit their use for patients with certain risk factors [22, 40,41,42,43]. The risk factors for the most important toxicity of NSAIDs—gastrointestinal bleeding, include older age, medical comorbidities and concomitant use of corticosteroids, selective serotonin reuptake inhibitors and anticoagulants [41, 44]. In addition, individuals with cardiovascular comorbidities are at risk for myocardial infarction, hypertension and heart insufficiency, while those with a renal condition are at risk of renal toxicity [40, 41].

Long-term use of NSAIDs is associated with several adverse effects, including alterations in renal function, effects on blood pressure, hepatic injury, and platelet inhibition, which may result in increased bleeding [10]. Although doses are recommended to be as low as possible, and NSAID treatment is continued for as short a time as possible [22], these treatment schedules do not serve as a valid option for long-term inflammation management as needed in OA. The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) guidelines suggest limiting non-selective NSAID use to a maximum of 7 days in patients with cardiovascular risk factors, with the Osteoarthritis Research Society International (OARSI) guidelines recommending against the use of any NSAID in these patients [45]. Guidelines advise prescribing proton-pump inhibitors (PPIs) to alleviate gastrointestinal side effects, but not other intestinal-related risks [41, 46]; however, longer-term intake of PPIs is also associated with adverse effects, e.g., small intestinal bacterial overgrowth and potentially increased risk for gastrointestinal malignancies [47]. The American Geriatrics Society recommends avoiding chronic use in patients over 65 years old, the typical age group for clinically relevant OA [48]. Selective COX-2 inhibitors should be limited to less than 30 days of use and the risk of hospitalization due to heart failure is reportedly doubled by all NSAID regimens including COX-2 inhibitors, according to the ESCEO [46]. The OARSI strongly advises against using COX-2 inhibitors in individuals with cardiovascular comorbidities [41]. Opioids as a final pharmacological treatment before surgery are either weakly or not at all recommended, owing to their unfavorable efficacy and/or safety profile [45] and were found to increase the risk of all-cause mortality [49].

As there is currently no cure for OA, affected patients face symptomatic and even worsening flares in the long term, and the most widespread therapy options have multiple limitations, particularly concerning adverse treatment effects. Coexistence of comorbidities is also frequent among patients with OA; up to 85% of patients present with one or more comorbidities, the most common ones being cardiovascular/blood diseases [50], emphasizing the need for an effective and well-tolerated anti-inflammatory treatment alternative to prevent OA progression and improve OA symptoms.

Treatments harboring complementary properties, including anti-inflammatory and analgesic effects that can improve mobility in patients with OA, such as OECs, have been proposed as valuable alternative options for patients with acute or chronic inflammation, with relatively mild adverse event profiles [13]. One well-researched OEC comprising a protease–flavonoid combination contains the proteolytic enzymes bromelain – a plant cysteine protease enzyme, and trypsin – an animal serine protease, combined with the plant flavonoid rutin (rutin trihydrate, or rutoside). This OEC has been proposed to reduce inflammation by helping to control the balance between pro-inflammatory and anti-inflammatory cytokines as outlined in the following sections, consequently improving symptoms associated with common inflammatory conditions.

Oral Proteolytic Enzyme Combination with Trypsin and Bromelain

Proteolytic enzymes do not suppress the inflammatory response but support and accelerate the controlled physiological progression of the immune response and inflammatory processes. In addition, they have a more favorable side-effect profile than NSAIDs [13]. Several potentially beneficial mechanisms underlying the effect of proteolytic enzymes in OECs have been proposed in animal models and in vitro (Table 1).

Table 1 Potential modes of action underlying the effect of proteolytic enzymes following oral application in animal models and in vitro

In vitro experiments have shown how OEC binding and activation of alpha-2-macroglobulin (alpha-2 M) cause the irreversible binding of excess cytokines, which are central to the inflammatory response in OA [15, 51, 52]. Secretion of pro-inflammatory cytokines decreased in the presence of bromelain [53]. Cell surface receptors such as CD44 associated with the inflammatory response in OA were shown to be removed by bromelain [54]. In addition, trypsin can reduce the concentration of advanced glycation end products (AGEs) [55], which have been found to accumulate in aged joints and are associated with OA [56] (Table 1).

High platelet count is associated with OA [57]. Animal models investigating inflammation have shown that bromelain can dissolve fibrin clots and reduce platelet aggregation [103]. In addition, animal models have demonstrated that enzyme formulations containing rutin, trypsin, and bromelain have antioxidant effects [104] (Table 1).

Pharmacodynamics of Orally Administered Enzymes

Alpha-2 M Activation by Proteases

Alpha-2 M is a plasma proteinase inhibitor with inflammatory properties that regulates the distribution and activity of many cytokines [58,59,60,61,62]. Though the exact mechanism is not known, animal models and human studies have demonstrated that proteolytic enzymes, such as trypsin and bromelain, are absorbed as physiologically intact molecules [63,64,65]. In the blood, these proteases bind to alpha-2 M, inducing a structural change that activates it. Cytokine-binding sites at the shoulder region of activated alpha-2 M are then exposed, allowing the irreversible binding of excess cytokines, such as interleukin-2 (IL-2), IL-6, IL-8, tumor necrosis factor-alpha (TNF-alpha) and IL-1 beta, restoring the balance necessary for suppressing inflammatory responses (Fig. 1) [51, 63, 66, 67]. Hypochlorite production in inflammation is considered an important switch mechanism to increase binding to pro-inflammatory cytokines and growth factors including IL-6, and decrease binding to cytokines and growth factors with anti-inflammatory in addition to pro-inflammatory roles such as transforming growth factor beta [51, 63]. When cytokines are bound to activated alpha-2 M, their activity is abolished [58]. This leads to a reduction of active cytokines in the blood. The enzyme–alpha-2 M–cytokine complexes are then degraded via macrophages and Kupffer cells. Proteolytic enzymes could therefore play a role in reducing inflammation by helping to restore the balance between pro-inflammatory and anti-inflammatory cytokines. Clinical evidence from a small number of healthy volunteers shows that ingestion of proteinases triggers the formation of an intermediate (enzyme-activated) form of alpha-2 M in blood plasma with preferential binding to the growth factor chosen [15]. Additionally, a significant reduction of IL-6 serum concentration was reported in a randomized, double-blind controlled trial after a 4-week intake of OEC in humans with subclinical inflammation [20]. A significant reduction of IL-1 beta and TNF-alpha was also observed in the serum of patients with rheumatoid arthritis who had been treated with an OEC in an open-label trial [68]. At present, there are ongoing investigations to determine the mechanism of action of this OEC in a randomized, double-blind, placebo-controlled, crossover trial in patients with OA ( NCT05038410) [69].

Fig. 1
figure 1

Proposed mode of action of enzymes in inflammation. Brom bromelain, TRY trypsin


Bromelain is a cysteine protease enzyme derived from pineapples [70]. It is an anti-inflammatory enzyme that reduces pro-inflammatory prostaglandin E2 and COX-2 synthesis [71]. Bromelain is used to treat OA and many other conditions, in addition to being used as an analgesic agent to treat muscular, arthritic and perineal pain, and pain from an episiotomy [72]. The analgesic effects of bromelain are believed to be caused by its direct effect on pain mediators, such as bradykinin [73, 74]. Downregulation of inflammatory cytokines and hence chondroprotective effects have been demonstrated in vitro in a porcine cartilage explant model and synovial sarcoma cell line [75].

At present, there are no large-scale RCTs investigating the benefits of bromelain as a single agent for the treatment of OA. In a randomized, single-blind, active-controlled, small pilot study where 40 patients with mild-to-moderate OA of the knee were randomized to receive oral bromelain (500 mg/day), or the NSAID diclofenac (gold standard therapy; 100 mg/day), there were similar reductions in the total Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain score and ratings for quality of life, as determined from the 36-item Short Form score, in the bromelain and diclofenac groups after 4 weeks; however, with the non-inferiority margin set at − 12%, the trial was inconclusive. These results suggest that bromelain was well tolerated, although two patients given diclofenac had adverse effects leading to discontinuation [76].

A systematic literature review and meta-analysis of six RCTs in third-molar surgery compared bromelain versus placebo or no treatment, and revealed that bromelain is an effective and safe adjuvant treatment for the control of post-operative pain [77]. The anti-inflammatory and analgesic characteristics of bromelain as an alternative to NSAIDs for post-operative pain control indicate its potential in the treatment of several chronic inflammatory disorders such as OA.


Trypsin is a serine protease enzyme isolated from porcine pancreatic juice and binds primarily to the specific anti-protease α1-antitrypsin, potentially increasing the bioavailability of plasmin for fibrinolysis and, through raised levels of anti-proteases, facilitates faster healing in combination with chymotrypsin [78]. Trypsin is transferred from its complex with α1-antitrypsin to alpha-2 M in vivo [79]. Oral trypsin may exhibit analgesic effects in arthritis patients through vagal mediation [80] and has shown anti-phlogistic effects [81] as demonstrated in mouse models. There are no RCTs investigating trypsin as single agent to treat OA, yet anti-inflammatory and analgesic synergistic effects of trypsin have been reported when used as a component of OECs [14, 78, 82, 83].


Rutin (other names: rutoside or rutin trihydrate), a plant flavonoid, has a number of pharmacological benefits including antioxidant effects, and has demonstrated anti-inflammatory properties in a rat model of acute and chronic inflammation [84,85,86]. Rutin is frequently used in combination with proteolytic enzymes in OECs to treat OA [14, 82, 83].

The plant flavonoid quercetin, a derivative of rutin, is currently under investigation as a senolytic drug. Senolytics are a class of drugs that specifically target senescent cells by inducing their apoptosis [87]. Quercetin has been reported to inhibit the development of senescent cells in pre-clinical studies and in an ongoing clinical study (in patients with chronic kidney disease) [36, 37, 88, 89]. Collectively, these studies of the senolytic properties of quercetin indicate the potential for this plant flavonoid in the treatment of OA.

Clinical Effect of an Oral Enzyme and Rutin Combination on OA

The OEC with the most available evidence for the treatment of OA comprises bromelain (450 International Pharmaceutical Federation [FIP] units; an internationally accepted unit to measure enzymatic activity), trypsin (1440 FIP units/24 µkat) and 100 mg of rutin.Footnote 1 This OEC has also been investigated to treat other types of inflammation (due to acute injuries), such as surgical trauma and soft tissue sports injuries [16, 19, 90]. Clinical studies on the efficacy and safety of the OEC with these doses of bromelain, trypsin, and rutin relative to the NSAID diclofenac are included in this review (Table 2) [13, 91,92,93,94,95,96]. Though there are other OECs that contain different enzyme components, or even only a combination of trypsin and chymotrypsin, these alternative combinations will not be discussed in this review due to lack of evidence.

Table 2 Summary of the findings of clinical trials (including a meta-analysis of six clinical trials) on the efficacy and safety of the oral enzyme combination of bromelain, trypsin, and rutin relative to the NSAID diclofenac

Clinical studies on the effect of this OEC in OA have reported positive treatment outcomes using the following outcome instruments: The Lequesne Algofunctional index (LAFI)—an internationally used, validated patient questionnaire for the self-assessment of OA-related joint pain and functional disability in daily life; the WOMAC scores; and the 11-point numeric rating scale (NRS11) for pain intensity. The LAFI and the numeric rating scale (NRS) are recommended by the European Medicines Agency [97]. A meta-analysis on individual raw patient data (N = 774) pooled from six RCTs compared OEC with the NSAID diclofenac in patients with knee OA [13]. The duration of treatment in the trials varied: 3 weeks in three trials, 6 weeks in two trials, and 12 weeks in one trial. The primary efficacy endpoint was the decrease in LAFI score. The OEC was demonstrated to have comparable efficacy to diclofenac in improving functional disability, mobility, and pain (Table 2) [13]. The mean ± standard deviation (SD) LAFI scores improved from 12.6 ± 2.4 at baseline to 9.1 ± 3.9 at study end (P < 0.001) and from 12.7 ± 2.4 to 9.1 ± 4.2 (P < 0.001) in the OEC and diclofenac groups, respectively. The absolute pain intensity (NRS11) differences at study end compared to baseline were also comparable: –3.5 ± 4.2 and –3.6 ± 4.3 in the OEC and diclofenac groups, respectively (not significant for either parameter) (Table 3) [13]. In addition, the proportions of patients reporting distinct LAFI response rates compared to baseline were comparable between the two treatment groups (Fig. 2) [13].

Table 3 Primary efficacy endpoint parameters from pooled reanalysis of patient reported data from prospective, randomized, double-blind, parallel-group studies in adult patients with moderate to severe osteoarthritis of the knee treated with an oral combination therapy or the gold standard nonsteroidal anti-inflammatory drug [13]
Fig. 2
figure 2

LAFI scores from pooled reanalysis of patient-reported data from prospective, randomized, double-blind, parallel-group studies in adult patients with moderate-to-severe osteoarthritis of the knee, treated with an oral enzyme combination or diclofenac, a nonsteroidal anti-inflammatory drug. Corresponding relative relief/improvement rates for the OEC vs. diclofenac. Data given for the intent-to-treat population (modified from Ueberall et al. 2016) [13]. LAFI Lequesne Algofunctional index, OEC oral enzyme combination

There was also a significant decrease (P < 0.001) in red blood count in 86.3% of the patients in the diclofenac group (vs. 18.8% of the OEC) and a significant increase (P < 0.001) in the mean of the values for liver enzymes aspartate aminotransferase, alanine aminotransferase, and gamma-glutamyl transferase in 72.6% patients in the diclofenac group (vs. 28.2% of the OEC; Fig. 3) [13]. The meta-analysis revealed significantly fewer adverse events in the OEC group compared to the diclofenac group (14.7% vs. diclofenac 21.1%); treatment-emergent adverse events leading to discontinuations were seen in 5.9% in the OEC group and 10.2% in the diclofenac group [13].

Fig. 3
figure 3

Change in safety-relevant laboratory parameters when treated with an OEC from pooled reanalysis of patient-reported data from prospective, randomized, double-blind, parallel-group studies in adult patients with moderate-to-severe osteoarthritis of the knee treated with an OEC or the gold-standard nonsteroidal anti-inflammatory drug (modified from Ueberall et al. 2016) [13]. Proportion (+ 95% confidence interval) of patients who presented with a decrease in hemoglobin, hematocrit, or erythrocytes, or an increase in AST, ALT, or GGT at study end versus baseline. Data given for the laboratory population and patients treated either with the OEC (white columns) or with diclofenac (black columns). AST aspartate aminotransferase, ALT alanine aminotransferase, CI confidence interval, GGT gamma-glutamyl transferase, OEC oral enzyme combination

The median number of rescue medication (paracetamol) tablets consumed was significantly lower in the OEC group compared to the diclofenac group (P < 0.05) in a randomized, double-blind, placebo- and comparator (diclofenac)-controlled trial investigating 150 patients with moderate to severe OA of the knee over a 12-week duration that was included in the meta-analysis [92]. Another study, also part of the meta-analysis, measured the difference in LAFI scores between the OEC and diclofenac groups at 7, 14, and 21 days of treatment from baseline, and reported no significant difference (P values for the difference in LAFI score between the two groups: 0.356, 0.219, 0.918, respectively). However, a clinical benefit of OEC compared with diclofenac was observed 4 weeks after the end of active treatment, with further reductions in LAFI score (P values for the difference in LAFI score: 0.033; Fig. 4) and overall pain symptoms in the OEC group (P = 0.024), while the parameters increased in the diclofenac group in this observation-only period (Fig. 4) [96]. In a double-blind, randomized, prospective, 6-week study included in the meta-analysis in 103 patients with OA of the knee, the subjective assessment of treatment tolerability was equivalent for both treatment groups: it was reported as “very good” or “good” by physicians and most patients in the OEC treatment group (89.2 and 84.2%, respectively) and in the diclofenac treatment group (86.0 and 86.0%, respectively) [91].

Fig. 4
figure 4

Sum of the Lequesne Algofunctional index score (average values over the treatment period) in a randomized, double-blind trial comparing an OEC or the gold-standard nonsteroidal anti-inflammatory drug in patients with osteoarthritis of the knee [96]. No significant differences were observed at baseline, 7, 14, or 21 days; P = 0.0165 at 49 days (observation period). OEC oral enzyme combination

Tilwe et al. [98] demonstrated the efficacy of the OEC versus diclofenac after a 3-week treatment period and a follow-up period 4 weeks after treatment for pain at rest, pain on movement, joint tenderness and swelling in 50 patients with OA of the knee (Table 2). Pain at rest and pain on movement were assessed subjectively. Joint tenderness was evaluated after applying finger pressure to the knee and joint swelling was recorded with measuring tape. At the end of the 3-week treatment period and during the 4-week follow-up period after treatment stopped, there was a reduction in pain joint tenderness (percentage change of 51.2 and 51.2% for OEC, and 19.5 and 27.8% for diclofenac, respectively), swelling (percentage change of 4.5 and 4.6% for OEC, and 2.1 and 1.0% for diclofenac, respectively) and in pain at rest (percentage change of 42.9 and 50.0% for OEC, and 25.8 and 32.2% for diclofenac, respectively) and pain on movement (percentage change of 39.6 and 37.5% for OEC, and 36.3 and 41.2% for diclofenac, respectively) (Table 2). The reduction in joint tenderness was significantly greater in the patients treated with OEC (P < 0.05) compared to patients treated with diclofenac [98].

Non-inferiority of oral administration of the OEC was also investigated compared to diclofenac (100 mg) in a randomized, double-blind trial of 90 patients with OA of the hip (Table 2) [99]. Within the 6-week treatment period, there were significant improvements in symptoms in both treatment groups based on LAFI score and on all WOMAC subscales (pain, joint stiffness, and physical function). The mean adjusted decreases from baseline to 6 weeks (difference ± standard error of the mean) were: WOMAC pain subscale (OEC – 10.3 ± 1.2; diclofenac – 9.5 ± 1.2), WOMAC joint stiffness subscale (OEC – 3.9 ± 0.5; diclofenac: – 3.6 ± 0.5), WOMAC physical function subscale (OEC – 31.7 ± 3.5; diclofenac: –29.7 ± 3.5) and LAFI score (OEC –2.9 ± 0.5; diclofenac: –2.3 ± 0.5). The global investigator assessments of treatment efficacy were reported as “very good” or “good” in 72.1% of the OEC group versus 61.4% of the diclofenac group (test of non-inferiority: P = 0.001). For most patients, the tolerability of both treatments was judged as “very good” or “good” (62.8% OEC vs. 50.0% diclofenac). This trial revealed significant evidence of non-inferiority of treatment with an OEC versus diclofenac after 6 weeks in patients with OA of the hip with regard to the WOMAC dimensions of pain, stiffness and physical function, LAFI score, the investigator and patients’ assessments of efficacy, and the responder rates based on pain and physical function.

A randomized clinical trial of 30 patients with temporomandibular joint (TMJ) OA examined the effectiveness of the OEC combined with the NSAID diclofenac sodium (50 mg) given to patients twice daily (b.i.d.) for 10 days. There were three treatment groups in this trial: patients were treated with the OEC and diclofenac combined (n = 10), OEC alone (n = 10) or diclofenac alone (n = 10). Pain scoring in this study utilized the NRS system [100]. The mean NRS pain score reduced from a mean score of 7.70 (SD 1.5) on day 1 to 2.8 (SD 1.2) by day 10 for the OEC group and from a mean of 8.80 (SD 1.2) to 3.40 (SD 1.4) by day 10 for the diclofenac group. In the adjunctive therapy patient group with diclofenac and OEC, the mean NRS pain score had notably reduced from a mean of 7.0 (SD 1.6) on day 1 to 0 by day 10. All treatment groups exhibited a decrease in pain from 7.8 ± 1.6 (mean ± SD) on day 1 to a mean of 2.1 ± 1.8 on day 10. There was no significant difference in pain management between the patients treated with OEC or diclofenac alone (P > 0.05). However, for the adjunctive therapy patient group treated with diclofenac and OEC, significantly improved pain management (P < 0.05) in patients with TMJ OA was reported compared to patients treated with NSAID or OEC alone (Table 2) [100].

Considering the positive outcomes of proteolytic enzymes in the treatment of OA, the efficacy and safety of bromelain has also been evaluated with the vegetal proteolytic enzyme papain (extracted from papaya fruits) for the treatment of lower back pain. In an RCT, 20 patients with lumbar spine OA were treated with the standard treatment—the NSAID aceclofenac (100 mg tablet b.i.d.) and 20 patients were treated with the NSAID (100 mg tablet b.i.d.) supplemented with bromelain and papain enzyme (250 mg b.i.d., unknown activity) [101]. Pain intensity measurements included the visual analogue scale (VAS). After 6 weeks of treatment, both groups reported significantly less pain (aceclofenac only: VAS 7.5 ± 1.1 to 7.0 ± 1.0; added enzyme combination: VAS 7.1 ± 1.3 to 5.9 ± 1.5; P = 0.001), and improvement in the Oswestry low back pain questionnaire (aceclofenac only: 54 ± 8.1 to 51 ± 8.5; added enzyme combination: from 56.2 ± 8.7 to 51.6 ± 8.1; P = 0.000) compared to baseline, and improved quality of life among other significant benefits [101]. However, no pre-defined non-inferiority margin was set to measure these similar effects. The safety of the proteolytic enzyme combination was confirmed by examining the effects on patients’ vital signs (no change, P > 0.05) and by the significant reduction of previously elevated liver/kidney enzyme alkaline phosphatase (210.0 ± 55.2 reduced to 196.9 ± 51.0; P = 0.054) and serum creatinine (1.0 ± 0.2 reduced to 0.9 ± 0.1; P = 0.035) values towards the normal range [101].


OA is a highly prevalent disease [102] often affecting older people with comorbidities. Comorbidities are a limiting factor for using NSAIDs in the management of pain in these patients with OA. Therefore, it is important to establish a pharmacological alternative to manage OA symptoms in combination with the recommended non-pharmacological modalities. Complementary approaches such as OECs could potentially lead to an improved quality of life in patients with OA as they can lead to the reduction of NSAID use in the OA population and decrease the risk of NSAID-induced cardiovascular and gastrointestinal adverse events.

This narrative review compiles evidence demonstrating that OEC is effective in reducing pain as evaluated with an NRS and improving algofunctional status as assessed by the Lequesne index score of patients with knee OA. Interestingly, OEC is effective on both pain at rest and in motion. The OEC is fast acting, as demonstrated by a significant effect in as little as 10 days of treatment for TMJ OA, and just 3 weeks of treatment for knee and hip OA [93,94,95,96, 98,99,100]. In addition, the efficacy of OECs is comparable to that observed with NSAIDs in knee OA [91, 93,94,95,96, 98]. Further, this rapidity of action distinguishes OEC from drugs of the slow-acting symptomatic drug class, including glucosamine and chondroitin, which are clinically efficient after 6–8 weeks according to studies.

The evidence also suggests that OECs are as efficient as diclofenac in reducing pain and improving function, and have a lower risk of adverse events compared to NSAIDs. This could be explained by the differences in their mechanisms of action. NSAIDs act by inhibiting COX-2 activity while OEC undertakes a dual mechanism of action, affecting alpha-2 M via enzyme activity and quercetin, a derivate of rutin, through its antioxidant activity. Since we know that the majority of the NSAID-related adverse effects are associated with the inhibition of COX activities in the small intestine and kidney, we can explain the better safety of OEC compared to diclofenac by a different mode of action. The comparator diclofenac (dose 100–150 mg/day), used in most studies, is considered as efficacious as ibuprofen, naproxen, celecoxib and etoricoxib, and can therefore serve as representative of this group of pain relievers [103].

As movement or training is an important factor in the management of OA, enabling untrained, less mobile patients to adhere to their recommended increased activity by potentially decreasing delayed-onset muscle soreness could be another aspect of the benefits of OEC; however, further investigation is required.

Indeed, there are some limitations to the conclusions of this review: the absence of testing OEC efficacy in specific OA animal models; the number of studies investigating OEC; and the small sample size of the studies included in the meta-analysis [13]. Since the meta-analysis was performed on pooled individual patient-level data, this enlarged the total sample size to a more relevant size and streamlined the data-reporting and evaluation procedures that varied across the six individual trials [91,92,93,94,95,96].

Further limitations include the lack of an adequate placebo group (however, efficacy results of the active comparator diclofenac were in line with data published) and the relatively short trial duration (up to 12 weeks) in the available OA studies. However, one study demonstrated continued OEC efficacy at least up to 4 weeks after treatment [96]. Long-term OEC safety (up to 2 years) has been seen in other conditions such as multiple sclerosis [104]. OEC therapy in patients with OA is considered a potentially effective option for long-term use owing to the need for sustained pain relief as the disease progresses.

A better understanding of how the mechanism of action of OEC therapy resolves acute inflammation is crucial to aid our understanding of how OEC therapy can also impact chronic tissue inflammation, including fibrosis. Furthermore, the potential structure-modifying effect of OEC therapy on joint tissue has not been demonstrated and there is a need to evaluate OEC therapy on pre-clinical models mimicking mechanically induced, inflammatory-related, or ageing-associated OA. This could be helpful in establishing OEC as a disease-modifying therapy for OA. At present, a placebo-controlled trial to study the mechanism of action of bromelain, trypsin, and rutin versus placebo in patients with OA is ongoing (EudraCT 2020–003,154-80). Another key uncertainty that needs to be addressed is the advantage of combining OEC and flavonoids.


In conclusion, OEC may serve as an effective treatment option for patients with OA due to its similar efficacy and more beneficial safety profile compared to NSAIDs such as diclofenac; however, further research is required.